DOI QR코드

DOI QR Code

Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients

  • Azim, Hamdy Abdel (Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University) ;
  • Abdal-Kader, Yasser Salah el din (Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University) ;
  • Mousa, Mohamed Mahmoud (Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University) ;
  • Malek, Raafat Abdel (Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University) ;
  • Abdalmassih, Michael Kheir (Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University) ;
  • Ibrahim, Noha Yehia (Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University)
  • Published : 2015.02.04

Abstract

Background: To evaluate the impact of adding taxanes to anthracycline-based regimens in the adjuvant setting in localized young female breast cancer patients on the overall survival (OS) and the disease free survival (DFS). Materials and Methods: This retrospective study included all female breast cancer patients who were candidates for adjuvant chemotherapy presenting to Kasr Al Ainy centre of clinical oncology and Cairo oncology centre (Cairo Cure) in the period from January 2005 till December 2010. Results: Our study included 865 patients, 732 of whom received anthracycline based regimens and 133 taxane based regimens. The mean age of patients was 39 years. After a median follow up of 50 months the median DFS was 48.4 months. Survival analysis indicated that the tumor size (>5cm vs. <5cm) p=0.001), nodal involvement (Yes vs. No) p=0.0001) and pathology (invasive lobular vs. ductal) p=0.048) affected DFS. As regards hormonal status, ER, PR and HER 2neu positive patients had longer DFS (p=0.001, 0.003, 0.106). On multivariate analysis DFS was affected by tumor size and lymph node involvement (p=0.014, 0.007). Subgroup analysis showed improvement in arms treated with taxanes in terms of DFS with positive Her2neu, ER and PR, but this was not statistically significant. Conclusions: Adding adjuvant taxanes to anthracyclines is beneficial for treatment of localized breast cancer among all subgroups, especially higher risk groups. The type of adjuvant chemotherapy regimens and tumor characteristics have direct effects on DFS.

Keywords

Breast cancer;Egypt;adjuvant chemotherapy;taxanes;her2neu;hormonal status

References

  1. Abd-El-Moneim NA, Abdelmoneim S, ElAlfy E (2011). Impact of comorbidity, hormonal receptor status and adjuvant chemotherapy plus tamoxifen versus tamoxifen alone on survival of senior breast cancer patients: retrospective study. J Geriatric Oncol, 2, 57.
  2. Abe H, Mori T, Kawai Y, Tomida K, Kubota Y et al (2014). Feasibility study of docetaxel and cyclophosphamide sixcycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients. Asian Pac J Cancer Prev, 14, 4835-38.
  3. Salem AAS, Salem MAE, Abbass H (2010). Breast cancer: surgery at the South Egypt Cancer Institute. Cancers, 2, 1771-8 https://doi.org/10.3390/cancers2041771
  4. Berry DA, Cirrincione C, Henderson IC, et al (2004). Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-Year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res Treat, 88,17. https://doi.org/10.1007/s10459-004-6006-2
  5. Cihan YB (2014). Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy. Asian Pac J Cancer Prev, 15, 4233-38. https://doi.org/10.7314/APJCP.2014.15.10.4233
  6. Citron ML, Berry DA, Cirrincione C et al (2013). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial/ CALGB 9741. J Clin Oncol, 21, 1431-39.
  7. Coudert B, Asselain B, Campone M et al (2012). UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for nodepositivebreast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist. 17, 900-9. https://doi.org/10.1634/theoncologist.2011-0442
  8. Dignam JJ, Dukic V, Anderson SJ et al (2009). Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat, 116, 595-602. https://doi.org/10.1007/s10549-008-0200-5
  9. El-Bolkainy MN (2000).Topographic pathology of cancer, 2nded. Cairo, National Cancer Institute, Cairo University:87.
  10. Elatar I.(2001). Cancer registration, NCI Egypt(2001).Cairo, Egypt, National Cancer Institute, 2002 (http://www.nci.edu.eg/ Journal/nci2001%20.pdf, accessed 1 April 2004)
  11. Faradmal J, Kazemnejad A, Khodabakhshi R, Gohary MR, Hajizadeh E.(2010). Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer. Asian Pac J Cancer Prev, 11, 353-58.
  12. Gogia A, Raina V, Deo SV et al (2014). Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: Institutional experience. Asian Pacific J Cancer Prev, 15, 1989-92. https://doi.org/10.7314/APJCP.2014.15.5.1989
  13. Hamza Abbas, Ashraf Elyamany, Mohamed Salem et al (2011). The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med, 4, 35. https://doi.org/10.1186/1755-7682-4-35
  14. Hassan BA, Yusoff ZB, Hassali MA, Othman SB, Weiderpass E (2012). Impact of chemotherapy on hypercalcaemia in breast and lung cancer patients. Asian Pacific J Cancer Prev, 13, 4373-78. https://doi.org/10.7314/APJCP.2012.13.9.4373
  15. Hayes DF, Thor AD, Dressler LG et al (2007). HER2 and response to Paclitaxel in node-positive breast cancer. New Engl J Med, 357, 1496-506. https://doi.org/10.1056/NEJMoa071167
  16. Ibrahim AS, Komodiki C, Najjar K, Rahamimoff R, Tuncer M (2002). Cancer Profile in Gharbiah, Egypt. Methodology and Results; Ministry of Health and Population Egypt and Middle East Cancer Consortium: Cairo, Egypt.
  17. Kim KJ, Huh SJ, Yang JH et al (2005). Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Jpn J Clin Oncol. 35, 126-33. https://doi.org/10.1093/jjco/hyi039
  18. Madarnas Y, Mates M, Agbassi C et al (2011). Adjuvant taxane therapy for women with early stage, invasive breast cancer. Evidence based series No.: 1-7 version 2. Toronto (ON): Cancer Care Ontario, 30.
  19. Mamounas EP, Bryant J, Lembersky B et al (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol, 23, 3686-96. https://doi.org/10.1200/JCO.2005.10.517
  20. McCredie, M, Coates M, Grulich A (1994).Cancer incidence in migrants to New South Wales (Australia) from the Middle East, 1972-1991. Cancer Causes Contr, 5, 414-21. https://doi.org/10.1007/BF01694755
  21. Montemurro F , Aglietta M (2009). Hormone receptor-positive early breast cancer: Controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer, 16, 1091-102. https://doi.org/10.1677/ERC-09-0033
  22. Omar S, Khaled H, Gaafar R et al (2003).Breast cancer in Egypt: A review of disease presentation and detection strategies. East Mediterr Health J, 9, 448-63.
  23. Peto R, Davies C, Godurin J et al (2012). Early breast cancer trialist's collaborative group (EBCTCG). Lancet, 379, 432-44. https://doi.org/10.1016/S0140-6736(11)61625-5
  24. Sakr H, Hamed RH, Anter AH, Yossef T (2013).Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome. Med Oncol, 30, 457. https://doi.org/10.1007/s12032-013-0457-3
  25. Seedhom AE, Kamal NN (2011). factors affecting survival of women diagnosed with breast cancer in El-Minia Governorate, Egypt. Int J Prev Med. 2, 131-38.
  26. Tai C, Pan CK, Chen CS et al ( 2014). Adjuvant trastuzumab for 6 months is effective in patients with HER2 positive stage II or III breast cancer. Asian Pacific J Cancer Prev, 14, 1981-84. https://doi.org/10.7314/APJCP.2013.14.3.1981

Cited by

  1. An update on the management of breast cancer in Africa vol.12, pp.1, 2017, https://doi.org/10.1186/s13027-017-0124-y